However, IT treatment with the drug primarily targets tumor vasculature increasing tumor vascular endothelial permeability resulting in PKC-dependent tumor vasculature hemorrhagic necrosis and rapid tumor ablation (8). The gene discussed is PRRT2; the disease is neoplasm.